EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trial
EXO Biologics will be funding the Phase I/II trial with €16m ($17.1m) gained through Series A funding.
Cygnus Technologies WP
Alphyn prepares for two global trials in atopic dermatitis
Direct Biologics’ ExoFlo shows decreased mortality in Covid-19 patients
FDA clears Direct Biologics’ IND to start ExoFlo Phase Ib/IIa trial
Direct Biologics unveils positive data from Covid-19 therapy programme
Innovent Biologics begins subject dosing in plaque psoriasis therapy trial
